Aseptic filling is a common solution to preparing sterile drug products when terminal sterilization is not possible. However, sterile filling can involve significant drug product loss. For high value drug products, where the active pharmaceutical ingredient (API) is either exceptionally expensive, complex to produce, or have long production lead times, this can be a significant concern.
In this white paper, we discuss how hold up volumes or losses can be minimized by determining the elements that contribute to them and working to minimize or eliminate each.